Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27528022 | 0.81 | HDAC3 (0.54) | LTB4R2CYP2C19HDAC6 | |
| SCHEMBL4652875 | 0.77 | CYP1A2 (0.58) | LTA4HALOX5PARP10NR4A1NR4A2 | |
| SCHEMBL9375612 | 0.74 | NOX1 (0.59) | ALOX5PARP10NR4A1NR4A2NR4A3 | |
| SCHEMBL5702266 | 0.73 | L3MBTL1 (0.63) | ALOX5PARP10PTGESNR4A1NR4A2 | |
| SCHEMBL153840 | 0.72 | L3MBTL1 (0.54) | ALOX5PTGESNR4A1NR4A2NR4A3 | |
| SCHEMBL9297926 | 0.71 | PARP10 (0.54) | LTA4HALOX5PARP10NR4A1NR4A2 | |
| Hydrochloric Acid SCHEMBL11551802 | 0.71 | PARP10 (0.57) | ALOX5PARP10PTGESNR4A1NR4A2 | |
| SCHEMBL5843729 | 0.71 | LTA4H (0.63) | LTA4HPARP10NR4A1NR4A2NR4A3 | |
| SCHEMBL2013554 | 0.71 | PARP10 (0.71) | LTA4HPARP10NR4A1NR4A2NR4A3 | |
| SCHEMBL17890895 | 0.71 | ALOX5 (0.51) | ALOX5PTGESNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1904484-B1 | COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080207638-A1 | Compounds | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207638-A1 | Compounds | CMA1, MRGPRX2, HRH2 | LTA4H 21/4885ALOX5 108/4885PARP10 3985/4885 |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | LTA4H 4357/4885ALOX5 4457/4885PARP10 441/4885 |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | LTA4H 204/4885ALOX5 2459/4885PARP10 1418/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | LTA4H 4357/4885ALOX5 4457/4885PARP10 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.